Gregg Boyle

This week the regulatory map redrew itself, and in opposite directions in adjacent agencies. HHS proposed rolling back AI health IT transparency requirements that have been the floor for vendor accountability since 2024. The FDA cleared the first continuous AI sepsis monitoring system with an 18% mortality reduction endpoint. MACPAC

Executive Read For operators, this week's signal is unambiguous. Ambient AI is no longer the question, workforce redesign around AI, clinical and back-office, is. Four deployment data points landed at named systems with documented achieved metrics, and they describe the new procurement reality. Abridge made nursing AI

This week, the regulator wrote the script. FDA opened the door on AI-monitored real-time clinical trials with named pharma collaborators. Science published peer-reviewed evidence of physician-level LLM reasoning. OpenEvidence, reportedly used by 40% of US physicians, pulled its product from the EU and UK over AI

While many still chased ambient AI headlines, the FDA, CMS, and a half-dozen state regulators continued to write the rules that determine which AI gets paid for, which gets enforced against, and which gets pulled. Procurement committees will now have a different rubric to use. Health systems already operating

This week the regulatory scaffolding for American healthcare AI arrived in a single five-day stretch. NCCN embedded an AI-derived risk threshold in cancer screening guidelines. FDA validated its first AI drug development tool. CMS wrote a national reimbursement pathway for a specific AI model. HSCC, IMDRF, ACCME, and

This week the healthcare AI landscape crossed a threshold. CMS created a reimbursement code for AI-detected coronary calcium. The FDA signaled it is moving toward post-market oversight. Four states advanced therapy chatbot bans. The WISeR Medicare pilot launched AI-powered claims review. And Q1 digital health funding hit